Show simple item record

dc.contributor.authorJalnapurkar, Isha
dc.contributor.authorFrazier, Jean A
dc.contributor.authorRoth, Mark
dc.contributor.authorCochran, David M
dc.contributor.authorFoley, Ann
dc.contributor.authorMerk, Taylor
dc.contributor.authorVenuti, Lauren
dc.contributor.authorRonco, Lucienne
dc.contributor.authorRaines, Shane
dc.contributor.authorCadavid, Diego
dc.date.accessioned2023-02-02T21:23:26Z
dc.date.available2023-02-02T21:23:26Z
dc.date.issued2022-12-09
dc.identifier.citationJalnapurkar I, Frazier JA, Roth M, Cochran DM, Foley A, Merk T, Venuti L, Ronco L, Raines S, Cadavid D. The feasibility and utility of hair follicle sampling to measure FMRP and FMR1 mRNA in children with or without fragile X syndrome: a pilot study. J Neurodev Disord. 2022 Dec 9;14(1):57. doi: 10.1186/s11689-022-09465-7. PMID: 36494616; PMCID: PMC9733195.en_US
dc.identifier.eissn1866-1955
dc.identifier.doi10.1186/s11689-022-09465-7en_US
dc.identifier.pmid36494616
dc.identifier.urihttp://hdl.handle.net/20.500.14038/51645
dc.description.abstractBackground: Fragile X syndrome (FXS) is the most common inherited cause of intellectual disability in males and the most common single gene cause of autism. This X-linked disorder is caused by an expansion of a trinucleotide CGG repeat (> 200 base pairs) on the promotor region of the fragile X messenger ribonucleoprotein 1 gene (FMR1). This leads to the deficiency or absence of the encoded protein, fragile X messenger ribonucleoprotein 1 (FMRP). FMRP has a central role in the translation of mRNAs involved in synaptic connections and plasticity. Recent studies have demonstrated the benefit of therapeutics focused on reactivation of the FMR1 locus towards improving key clinical phenotypes via restoration of FMRP and ultimately disease modification. A key step in future studies directed towards this effort is the establishment of proof of concept (POC) for FMRP reactivation in individuals with FXS. For this, it is key to determine the feasibility of repeated collection of tissues or fluids to measure FMR1 mRNA and FMRP. Methods: Individuals, ages 3 to 22 years of age, with FXS and those who were typically developing participated in this single-site pilot clinical biomarker study. The repeated collection of hair follicles was compared with the collection of blood and buccal swabs for detection of FMR1 mRNA and FMRP and related molecules. Results: There were n = 15 participants, of whom 10 had a diagnosis of FXS (7.0 ± 3.56 years) and 5 were typically developing (8.2 ± 2.77 years). Absolute levels of FMRP and FMR1 mRNA were substantially higher in healthy participants compared to full mutation and mosaic FXS participants and lowest in the FXS boys. Measurement of FMR1 mRNA and FMRP levels by any method did not show any notable variation by collection location at home versus office across the various sample collection methodologies of hair follicle, blood sample, and buccal swab. Conclusion: Findings demonstrated that repeated sampling of hair follicles in individuals with FXS, in both, home, and office settings, is feasible, repeatable, and can be used for measurement of FMR1 mRNA and FMRP in longitudinal studies.en_US
dc.language.isoenen_US
dc.relation.ispartofJournal of Neurodevelopmental Disordersen_US
dc.relation.urlhttps://doi.org/10.1186/s11689-022-09465-7en_US
dc.rights© The Author(s) 2022. Open Access: This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativeco mmons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.en_US
dc.rightsAttribution 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectClinical biomarkeren_US
dc.subjectFMR1 mRNAen_US
dc.subjectFMRPen_US
dc.subjectFragile Xen_US
dc.subjectHair follicleen_US
dc.titleThe feasibility and utility of hair follicle sampling to measure FMRP and FMR1 mRNA in children with or without fragile X syndrome: a pilot studyen_US
dc.typeJournal Articleen_US
dc.source.journaltitleJournal of neurodevelopmental disorders
dc.source.volume14
dc.source.issue1
dc.source.beginpage57
dc.source.endpage
dc.source.countryUnited States
dc.source.countryEngland
dc.identifier.journalJournal of neurodevelopmental disorders
refterms.dateFOA2023-02-02T21:23:27Z
dc.contributor.departmentEunice Kennedy Shriver Centeren_US
dc.contributor.departmentPsychiatryen_US


Files in this item

Thumbnail
Name:
s11689-022-09465-7.pdf
Size:
1.273Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

© The Author(s) 2022. Open Access: This article is licensed under a Creative Commons Attribution 4.0 International License, which
permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the
original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or
other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line
to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this
licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativeco
mmons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Except where otherwise noted, this item's license is described as © The Author(s) 2022. Open Access: This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativeco mmons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.